TransEnterix Inc. was initially incubated under the Synecor LLC umbrella, a medical technology accelerator located in Research Triangle Park, North Carolina.
With a state-of-the-art prototyping facility, TransEnterix is well positioned to rapidly execute on design inputs from visiting surgeons, who test new products in pre-clinical labs to evaluate form and function. Their input was crucial for the development of single port, multi-channel prototypes that allowed for rapid verification of proof of concepts.
Investors in TransEnterix include: SV Life Science Advisers, Synergy Life Science Partners, Aisling Capital, Intersouth Partners, and Quaker BioVentures. as new investors, as well as current investors.
Founded in 2000, Synecor, LLC, is a privately held and highly successful business accelerator. The company focuses on creating highly proprietary and disruptive technologies in the largest medical device and combination drug/device markets. More information is available at www.synecor.com.
Aisling Capital is a leading private equity fund, with $1.6 billion under management, that invests in products, technologies, and global businesses that advance health. Aisling Capital is led by a group of investment professionals with diverse backgrounds in industry, science and finance. The team's complementary backgrounds give Aisling Capital unique perspective on the key players, events and forces shaping the life science industry, and allow the fund to identify investment opportunities. In working with portfolio companies, the principals of Aisling Capital seek to provide the financing, relationships and guidance needed to build highly successful companies. To learn more, visit www.aislingcapital.com.
Located in Durham, N.C., Intersouth Partners is one of the largest, most active and most experienced early-stage venture funds in the country, having invested in more than 100 private companies over the last two decades. Founded in 1985, Intersouth Partners manages $780 million in seven venture capital limited partnerships. Intersouth seeks a broad range of seed and early-stage investment opportunities throughout the Southeast, focusing on the technology and life sciences sectors. Visit www.intersouth.com for more information.
Quaker BioVentures is a venture capital firm with $700 million under management, dedicated to investing in life-science companies in the Mid-Atlantic region and contiguous states. The firm leads investments in companies across the spectrum of the life-science industry, including biopharmaceuticals, medical devices, human diagnostics, specialty pharmaceuticals and health-care services. Quaker BioVentures invests in companies at all stages of development, from early-stage businesses to public companies. To learn more, visit www.quakerbio.com.
SV Life Sciences, formerly Schroder Ventures Life Sciences, is a global leader in international life-sciences investing. SVLS affiliated funds have been investing in life-sciences companies since the early 1980s and SVLS formed its first dedicated life-sciences fund in 1994. The SVLS team manages five venture capital funds and a publicly traded investment trust with approximately $2 billion of capital commitments. SVLS employs a diversified strategy within life sciences in order to selectively capitalize on an expanding opportunity in biotech, medical devices and health-care services. Visit www.svlsa.com to learn more.
Synergy Life Science Partners is a venture capital firm that helps to form and invests in early-stage medical device companies. It takes a synergistic approach with entrepreneurs to build valuable companies through direct investment, by leveraging its network and applying the partnerships technical, clinical and operational expertise. To learn more, visit www.synergylsp.com.